AMY BELNAP: Open Payments
NPI 1699202044 · CHUBBUCK, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$335,177 in 441 payments from 14 companies in 2025. Trend: 2023 $37,969 · 2024 $180,758 · 2025 $335,177
Speaker / faculty: $249,287Travel & lodging: $39,858Honoraria: $19,339Consulting: $18,928Food & beverage: $7,766
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 145 | $139,121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 143 | $105,392 |
| E.R. Squibb & Sons, L.L.C. | 68 | $64,783 |
| Axsome Therapeutics, Inc. | 39 | $24,880 |
| ABBVIE INC. | 21 | $278 |
| Tris Pharma Inc | 4 | $262 |
| Teva Pharmaceuticals USA, Inc. | 6 | $169 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| Vanda Pharmaceuticals Inc. | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
Products named: INGREZZA, CAPLYTA, COBENFY, Auvelity, VRAYLAR, Dyanavel XR, UZEDY, FANAPT.
Industry payments across ID — which companies pay providers there.
